The latest news from oncology events around the world
Two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to…
Based on guidance from biomarker screening, patients who are 55 years of age and older…
Use of high-dose ifosfamide (Ifex) was found to be superior for treating recurrent and primary refractory…
The use of trastuzumab deruxtecan (Enhertu), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared…
The use of panitumumab (Vectibix) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic…
The use of autologous stem cell transplant (ASCT) early in the course of treatment showed…
A team of researchers from SWOG Cancer Research Network, a cancer clinical trials group funded…
Tumours from desmoplastic melanoma, a rare cancer most commonly found on the head or neck,…
Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or…
A novel combination of two experimental cancer immunotherapy agents along with an immune checkpoint blocker…